Bangladesh Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Bangladesh Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Bangladesh Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: While Bangladesh's ambitious goals for pharmaceutical exports are unlikely to be realised, the sector will see modest growth ahead. Emerging markets such as Myanmar will be stable sources of demand even as opportunities to export to the lucrative developed markets such as the US and the EU grow due to cost containment. A key risk to this stems from the commoditisation of the generic drug sector, which will place pressure on profit margins, and the competition from the more established Indian pharmaceutical sector.

Headline Expenditure Projections

  • Pharmaceuticals: BDT171.6bn (USD2.2bn) in 2015 to BDT190.8bn (USD2.4bn) in 2016; +11.2% in local currency terms and +9.1% in US dollar terms.

  • Healthcare: BDT494.0bn (USD6.3bn) in 2015 to BDT554.9bn (USD7.0bn) in 2016; +12.3% in local currency terms and +10.3% in US dollar terms.

Headline Pharmaceuticals & Healthcare Forecasts (Bangladesh 2014-2020)
2014 2015e 2016f 2017f 2018f 2019f 2020f
f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 1.989 2.195 2.395 2.621 2.865 3.128 3.413
Pharmaceutical sales, % of GDP 1.15 1.13 1.10 1.08 1.06 1.04 1.02
Pharmaceutical sales, % of health expenditure 35.2 34.7 34.4 34.1 34.0 33.9 34.0
Health spending, USDbn 5.646 6.318 6.967 7.678 8.429 9.219 10.048

Risk/Reward Index

In Q216 Bangladesh's Risk/Reward Index (RRI) score remains unchanged from last quarter at 41.8 out of 100. Bangladesh also retains its ranking position in BMI's RRI matrix, standing as the 15th most attractive market to pharmaceutical investors out of 19 markets in the Asia Pacific region. Bangladesh's score is driven by a large pharmaceutical market (market expenditure score of 10.0 out of 20) and rapid drug market expansion (sector value growth score of 8.4 out of 12), but dragged down by low levels of drug spending per capita (spending per capita score of 1.2 out of 12) and limited intellectual property protection (patent respect score of 1.4 out of 7).

Latest Updates

February 2016

  • In February 2016, the Bangladesh Minister of Health noted that the country is at risk of a spread of swine flu following an outbreak in India.

  • February also saw calls by health rights groups to implement strong regulations governing the private sector. Acknowledging the shortcomings in the sector, authorities have noted that they intend to update their monitoring mechanism.

  • In January 2016, The Export Promotion Bureau (EPB) reporting in January 2016 that medicine exports for the first six months of FY2015/16 (July 2015 to December 2015) amounted to BDT3bn (USD38mn). According to the EPB, this amount was 18% higher than the same period last year.

BMI Economic View

Bangladesh's economy will likely grow by 6.5% in FY2015/16 (July-June), similar to the rate in FY2014/15, on the back of robust expansions in the industrial and services sectors. However, the global economic slowdown and domestic security threats pose downside risks to our optimistic view.

BMI Political View

The recent series of domestic terror attacks in Bangladesh could pose downside risks to political stability as the ruling Awami League appears to be trying to gain political mileage by putting the blame on the opposition Bangladesh Nationalist Party. The rise of domestic security threats could also have an adverse impact on the country's economic recovery as it could deter investors and weigh on the tourism sector.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Bangladesh 2014-2020)
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Bangladesh 2012-2020)
13
Healthcare Market Forecast
14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Bangladesh 2012-2020)
16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Bangladesh 2012-2020)
16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Bangladesh 2012-2020)
17
Prescription Drug Market Forecast
18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Bangladesh 2012-2020)
19
Patented Drug Market Forecast
20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Bangladesh 2012-2020)
21
Generic Drug Market Forecast
22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Bangladesh 2012-2020)
23
OTC Medicine Market Forecast
24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Bangladesh 2012-2020)
25
Pharmaceutical Trade Forecast
26
Table: Pharmaceutical Trade Data And Forecasts (Bangladesh 2014-2020)
28
Table: Pharmaceutical Trade Data And Forecasts local currency (Bangladesh 2014-2020)
28
Pharmaceuticals & Healthcare Risk/Reward Index
29
Asia Pacific Risk/Reward Index
29
Bangladesh Risk/Reward Index
35
Rewards
35
Risks
36
Regulatory Review
37
Table: Steps To Establish A Pharmaceutical Manufacturing Unit And Obtain A Drug Manufacturing Licence
39
Intellectual Property Issues
39
Pricing And Reimbursement Regime
41
Market Overview
44
Healthcare Sector
44
Healthcare Infrastructure
51
Table: Healthcare Resources (Bangladesh 2010-2015)
51
Table: Healthcare Personnel (Bangladesh 2010-2015)
51
Table: Healthcare Activity (Bangladesh 2010-2015)
52
Research And Development
53
Table: Suggestions Made By University Of Dhaka's Faculty Of Pharmacy To Improve Pharmaceutical Research
54
Clinical Trials
55
Epidemiology
56
Competitive Landscape
59
Research-Based Industry
59
Table: Table: Multinational Market Activity
62
Pharmaceutical Distribution
63
Company Profile
64
Beximco Pharmaceuticals
64
Eskayef
67
Renata
70
Sanofi
73
Square Pharmaceuticals
76
Demographic Forecast
79
Table: Population Headline Indicators (Bangladesh 1990-2025)
80
Table: Key Population Ratios (Bangladesh 1990-2025)
80
Table: Urban/Rural Population & Life Expectancy (Bangladesh 1990-2025)
81
Table: Population By Age Group (Bangladesh 1990-2025)
81
Table: Population By Age Group % (Bangladesh 1990-2025)
82
Glossary
84
Methodology
86
Pharmaceutical Expenditure Forecast Model
86
Healthcare Expenditure Forecast Model
86
Notes On Methodology
87
Risk/Reward Index Methodology
88
Index Overview
89
Table: Pharmaceutical Risk/Reward Index Indicators
89
Indicator Weightings
90

The Bangladesh Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Bangladesh Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Bangladesh pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Bangladesh, to test other views - a key input for successful budgeting and strategic business planning in the Bangladeshi pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Bangladeshi pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Bangladesh.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.